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The Impact of Thiazolidinedione
Use on Outcomes in Ambulatory
Patients With Diabetes Mellitus and Heart Failure
David Aguilar, MD,* Biykem Bozkurt, MD, FACC,*† Allison Pritchett, MD, FACC,*
Nancy J. Petersen, PHD,† Anita Deswal, MD, MPH, FACC*†‡
Houston, Texas
Objectives This study sought to examine the relationship between thiazolidinedione (TZD) use and outcomes in ambulatory
patients with diabetes and heart failure (HF).
Background Thiazolidinediones have been relatively contraindicated in diabetic patients with HF.
Methods We conducted a retrospective study of a national cohort of veterans with HF and diabetes treated in ambulatory
clinics at Veterans Affairs medical centers. Patients were classified into those using TZDs and those not using
insulin-sensitizing medication based on prescriptions filled 90 days before or 30 days after the index outpatient
visit. The outcomes were time to hospitalization for HF and time to death.
Results Of 7,147 ambulatory HF patients receiving diabetic therapy, 818 (11.4%) were receiving a TZD and 4,700
(65.8%) were not receiving insulin sensitizers. Over 2 years of follow-up, 134 (16.4%) patients receiving TZDs
and 741 (15.8%) patients not receiving insulin-sensitizing medications required HF hospitalization (adjusted haz-
ard ratio 1.00, 95% confidence interval 0.81 to 1.24, p  0.97). A total of 168 (20.5%) patients receiving TZDs
and 1,192 (25.4%) patients not receiving insulin-sensitizing medications died (adjusted hazard ratio 0.98, 95%
confidence interval 0.81 to 1.17, p  0.80).
Conclusions In ambulatory patients with established HF and diabetes, the use of TZDs was not associated with an in-
creased risk of HF hospitalization or total mortality when compared with those not receiving insulin-
sensitizing medications. (J Am Coll Cardiol 2007;50:32–6) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.096s
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(iabetes mellitus and heart failure (HF) commonly coexist
ith a prevalence of diabetes in major HF trials of approx-
mately 20% to 30% (1). Importantly, the coexistence of
iabetes and HF portends a poor prognosis (2). Because of
his adverse prognosis, efforts to adequately treat diabetes in
ndividuals with HF become increasingly important.
See page 37
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007, accepted January 16, 2007.Thiazolidinediones (TZDs), agonists for the nuclear tran-
cription factor peroxisome-proliferator-activated receptor ,
ave emerged as a therapeutic option in the treatment of
iabetes (3). In addition to beneficial effects on insulin sensi-
ivity and glucose homeostasis, activation of the peroxisome-
roliferator-activated receptor  system results in myriad po-
entially beneficial metabolic (3), vascular (4,5), and
eurohormonal effects (6,7) that may be advantageous in the
revention of HF and/or treatment of diabetes in those with
stablished HF. Despite these potential benefits, TZD use has
een associated with increased weight gain and fluid retention
8) and some reports of increased HF (9–11). Because of
hese concerns, TZD use is not recommended for pa-
ients with New York Heart Association functional class
II or IV symptoms (8).
Limited data exist regarding the association of TZDs and
F outcomes in diabetic patients with established HF
12,13), particularly in ambulatory patients with HF. We
ought to determine the relationship between TZD use and
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ensitizing agents in a national cohort of ambulatory pa-
ients with diabetes and HF treated at Veterans Affairs
VA) medical centers.
ethods
tudy design and sample. We performed a retrospective
tudy of a national cohort of veterans with HF treated in
mbulatory clinics at VA medical centers using the VA
xternal Peer Review Program (EPRP) data between Oc-
ober 2000 and September 30, 2002. As described in detail
reviously (14,15), the sampling pool of outpatients for
PRP included ambulatory patients with common chronic
iseases such as HF, diabetes, ischemic heart disease, and
hronic obstructive pulmonary disease (COPD) identified
y specific ICD-9 codes. Abstractors reviewed electronic
edical records for validation of inclusion criteria, including
ocumentation of an HF diagnosis in outpatient charts (15).
atient-level data from the EPRP HF cohort was linked
ith 5 existing national VA databases to obtain further
emographic, laboratory, pharmacy, and outcome data.
Individuals from the EPRP HF cohort who had diabetes
as identified in the EPRP data) and were prescribed
ypoglycemic medications (in the pharmacy database) were
ncluded. Diabetic therapy was ascertained using pharmacy
ata and was based on prescriptions filled 90 days before or
0 days after the index outpatient visit, and individuals were
lassified as users of TZDs and users of non–insulin-
ensitizing antihyperglycemic medications. In addition,
aseline demographics and concomitant cardiac medica-
ions were assessed at the index visit. Most recent laboratory
ata within 1 year before and up to 2 weeks after the index
isit were used. Glomerular filtration rate was calculated
sing the 4-variable Modification of Diet in Renal Disease
quation (16). Covariates that reflected diabetes severity
ncluded hemoglobin A1c and a variable documenting a
iabetic complication including neuropathy, nephropathy,
etinopathy, or peripheral vascular disease.
Our comparison groups were composed of patients re-
eiving TZDs versus those patients not receiving insulin-
ensitizing medications. Because of the potential confound-
ng effects of biguanide therapy (12), we excluded
ndividuals receiving biguanide therapy in the absence of
oncomitant TZD therapy (n  1,629). The primary
utcome was time to hospitalization for HF, and the
econdary outcome was time to death over 2 years of
omplete follow-up after the index outpatient visit.
tatistical analysis. Differences in baseline variables were
scertained using chi-square tests for categorical variables
nd t tests for continuous variables. Two-sided p values 
.05 were considered statistically significant. Univariate and
ultivariable Cox proportional hazards models were used to
ssess the relationship between diabetic therapy with TZD
ompared with non–insulin-sensitizing agents and the out-
omes of interest. Multivariable Cox proportional hazards todels were constructed using
orward stepwise selection with
ariables with p  0.1 being
ntered into the model. Candi-
ate variables included age, gen-
er, body mass index, left ven-
ricular ejection fraction (LVEF),
lomerular filtration rate, hemo-
lobin, hyponatremia, hemoglo-
in A1c, race, prior diabetic
omplications, atrial fibrillation,
ngiotensin-converting enzyme
nhibitor or angiotensin II recep-
or blocker use, beta-blocker use,
tatin use, prior HF hospitaliza-
ion, hypertension, cancer, prior
yocardial infarction, COPD, peripheral vascular disease,
ementia, psychiatric disorders, severe liver disease, rheu-
atologic disease, medical school affiliation, and additional
iabetic therapy. Missing laboratory values were imputed
sing the median value of the study cohort for that param-
ter (missing  418 for serum sodium, 713 for serum
reatinine, and 1,208 for hemoglobin), and a dummy
ariable was used to indicate replacement of missing data.
odels including only patients without missing laboratory
ata yielded no significant change in overall results. Statis-
ical analysis was performed using SAS software 9.1 (SAS
nstitute Inc., Cary, North Carolina).
esults
aseline characteristics. A total of 7,147 ambulatory HF
atients with diabetes requiring diabetic therapy were iden-
ified. Of these, 818 (11.4%) patients were receiving a TZD,
,837 (25.7%) patients were receiving a biguanide, and
,700 (65.8%) patients were not receiving insulin sensitizers.
he 1,629 individuals who were receiving biguanide therapy
n the absence of TZDs were excluded from the study.
The TZD users were younger, had a higher body mass
ndex, and were more likely to have a higher LVEF and to
ave had a prior diabetic complication than those who were
ot receiving insulin-sensitizing medications (Table 1). The
ZD users were less likely to have cancer, atrial fibrillation,
OPD, a prior myocardial infarction, or a HF hospitaliza-
ion within 2 years before the index visit. In addition, they
ad a lower hemoglobin and a higher hemoglobin A1c, and
ere more likely to receive statin therapy, but less likely to
eceive care in a VA center affiliated with a medical school
han those not receiving insulin sensitizers.
utcomes. Over 2 years of follow-up, 134 (16.4%) pa-
ients receiving TZDs and 741 (15.8%) patients not receiv-
ng insulin-sensitizing medications required HF admission
p  0.79). After adjusting for age and other covariates, no
ignificant difference was noted in the rate for HF hospi-
Abbreviations
and Acronyms
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
EPRP  External Peer
Review Program
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
TZD  thiazolidinedione
VA  Veterans Affairsalization between the 2 groups (risk-adjusted hazard ratio
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.97) (Table 2).
Furthermore, 168 (20.5%) patients receiving TZDs and
,192 (25.4%) patients not receiving insulin-sensitizing
aseline Characteristics of the Study Cohort
Table 1 Baseline Characteristics of the Study Cohort
TZD
(n  818)
No Insulin-
Sensitizing
Medication
(n  4,700)
Age, yrs (SD) 67.6 (9.4) 70.3 (9.3)*
Male (%) 774 (95) 4,397 (94)
Race (%)
White 625 (76) 3,491 (74)*
Black 67 (8) 596 (13)
Other/unknown 126 (15) 613 (13)
Systolic blood pressure, mm Hg (SD) 130.9 (21.3) 131 (21.6)
Body mass index, kg/m2 (SD) 34.3 (7.6) 31.0 (6.5)*
LVEF (%)
Normal or mildly reduced (LVEF 40%) 430 (52) 2,004 (43)*
Moderate or severely reduced (LVEF 40%) 261 (32) 1,844 (39)
Unknown 127 (16) 852 (18)
Diabetes with complications (%) 537 (66) 2,647 (56)*
Dementia (%) 10 (1.2) 133 (2.8)*
Atrial fibrillation (%) 199 (24) 1,412 (30)*
Past myocardial infarction (%) 314 (38) 1,627 (35)†
Chronic obstructive pulmonary disease (%) 178 (22) 1,332 (28.3)*
Cancer (%) 120 (14.7) 871 (18.5)*
GFR, ml/min/m2 (SD)
60 291 (36) 1,686 (36)
30 to 60 436 (53) 2,514 (53)
30 91 (11) 500 (11)
Sodium (mEq/l) 138.7 (3.4) 138.9 (3.4)
Hemoglobin, mg/dl (SD) 13.1 (1.8) 13.3 (1.8)*
Hemoglobin A1c, % (SD) 8.0 (1.7) 7.5 (1.6)*
Medication use (%)
Insulin 437 (53) 2,483 (53)
Sulfonylurea 405 (50) 2,824 (60)
Biguanide 208 (25) 0*
ACE or ARB 676 (83) 3,841 (82)
Statin 558 (68) 2,516 (54)*
Beta-blocker 496 (61) 2,847 (61)
Prior HF hospitalization within 2 yrs (%) 135 (17) 930 (20)†
Medical school affiliation (%) 467 (57) 2,985 (64)*
p  0.01; †p  0.05.
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; GFR 
lomerular filtration rate; HF  heart failure; LVEF  left ventricular ejection fraction; TZD 
hiazolidinedione.
eart Failure Hospitalization and Mortality by Diabetic Drug Catego
Table 2 Heart Failure Hospitalization and Mortality by Diabetic
Heart Failure Hospit
TZD
(n  818)
N
2-yr outcome (%) 134 (16.4)
Unadjusted hazard ratio (95% CI) 1.03 (0.85–1.23)
Age-adjusted hazard ratio (95% CI) 1.01 (0.84–1.21)
Fully adjusted hazard ratio (95% CI) 1.00 (0.81–1.24)azard ratio compares heart failure hospitalization or death in patients on TZDs versus patients not on T
CI  confidence interval; TZD  thiazolidinedione.edications died during follow-up (p  0.003). However,
he risk-adjusted mortality rates were not significantly
ifferent between the 2 groups (risk-adjusted HR 0.98, 95%
I 0.81 to 1.17, p  0.80) (Table 2).
Additional analyses were performed using Cox propor-
ional hazard models in specific subgroups based on age,
VEF, renal insufficiency, concomitant insulin use, and
rior HF hospitalization (Fig. 1). No statistically significant
nteraction was noted between subgroups with the exception
f concomitant insulin use and HF hospitalization. In those
atients not receiving insulin therapy (n  2,598), TZD
as associated with a higher risk of HF hospitalization
ompared with those not receiving insulin-sensitizing med-
cations (HR 1.62, 95% CI 1.15 to 2.29, p value for
nteraction  0.03) (Fig. 1).
iscussion
espite the common coexistence of HF and diabetes, few
tudies have examined the safety and efficacy of TZDs in
ndividuals with established HF. In a smaller study of
iabetic patients with systolic HF who were treated with
ZDs, 17% developed fluid retention, a finding that tended
o be more peripheral and appeared reversible after drug
ithdrawal (13). In a more recent large retrospective cohort
tudy of Medicare beneficiaries with diabetes with a prin-
ipal hospital discharge diagnosis of HF, TZD use was
ssociated with a 13% reduced risk of death, despite a
orderline increased risk of HF readmission (HR 1.06, 95%
I 1.00 to 1.09) (12).
Our study extends the current body of literature regarding
ZD use and HF to include a large cohort of ambulatory
atients with established HF treated in VA medical centers.
imilar to the study of Medicare beneficiaries (12), TZD
se in individuals with established HF was relatively com-
on and occurred in approximately 1 in 9 patients. Con-
rary to previous concerns, we found no evidence for
ncreased rates of HF admission in diabetic HF patients
reated with TZDs when compared with those patients who
ere not receiving insulin-sensitizing diabetic therapy. The
nadjusted risk of death was reduced in those receiving
ZD therapy, but was no longer significant in age-adjusted
nd fully adjusted models. The difference in results in
ortality between this study and that of Masoudi et al. (12)
Category
n Death
lin-Sensitizing
dication
4,700)
TZD
(n  818)
No Insulin-Sensitizing
Medication
(n  4,700)
1 (15.8)* 168 (20.5) 1,192 (25.4)†
1.0 0.78 (0.67–0.92) 1.0
1.0 0.85 (0.72–1.00) 1.0
1.0 0.98 (0.81–1.17) 1.0ry
Drug
alizatio
o Insu
Me
(n 
74ZDs. *p  0.79; †p  0.003.
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mbulatory patients compared with the cohort of recently
ospitalized patients in the Medicare database.
In exploratory subgroup analyses, an increased risk of HF
ospitalization was seen associated with TZD use in the
roup of diabetic patients not receiving insulin therapy.
his finding contrasts previous data that suggest that
nsulin use is associated with more TZD-associated fluid
etention in the general population (8) and in a smaller
utpatient HF population (13). In the study by Masoudi
t al. (12) of recently hospitalized Medicare patients, the
isk of readmission for HF was similar among TZD
atients treated with insulin and those not treated with
nsulin. Our finding may be a chance-related finding
iven the multiple analyses performed, but future studies
ill need to further explore risks and benefits of TZD use
n various subgroups.
tudy limitations. This study has limitations inherent to
etrospective observational studies. Although multivariable
tatistical models were use to adjust for heterogeneity
etween groups, residual unmeasured confounding factors
ay remain. The younger age, lower frequency of prior HF
ospitalization, and higher frequency of preserved LVEF in
he TZD group may suggest less severe HF in this group
ompared with those using non–insulin-sensitizing medica-
ions. However, availability of LVEF, blood pressure, and
aboratory data should provide robust risk-adjustment vari-
bles. Although the randomized clinical trials underway will
e instrumental in defining the benefit-to-risk ratio of
ZDs in HF, randomized trials may exclude patients
Figure 1 Hazard Ratios for HF Hospitalization or Death in Subg
of Patients on TZDs Versus Patients Not Receiving In
Subgroup analyses showing hazard ratios of heart failure (HF) hospitalization or de
versus patients not receiving insulin sensitizers. *Interaction p value  0.03. GFRncluded in observational studies, such as those patients with
Edvanced renal insufficiency. Finally, the primary end point
f this study was HF hospitalization, and episodes of HF
xacerbation that did not require hospitalization were not
aptured.
onclusions
n an ambulatory cohort of patients with established HF
nd diabetes, TZD use was not associated with an increased
isk of HF hospitalization or with increased risk of death
hen compared with those not receiving insulin-sensitizing
edications. Our data suggest that TZDs may be used
afely in individuals with stable HF, and that TZDs could
e included in the armamentarium to adequately treat
iabetes in this group. However, until data from adequately
owered randomized clinical trials are available to define the
enefits and risks associated with TZDs, clinicians treating
ndividuals with diabetes and HF must remain cautious
hen using this class of medications.
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